BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.83%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.15B
AUM Growth
+$6.15B
(-6.1%)
Cap. Flow
-$279M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
65
Reduced
60
Closed
12
Top Buys
| 1 |
Stryker
SYK
|
$32.9M |
| 2 |
Biohaven
BHVN
|
$30.9M |
| 3 |
UnitedHealth
UNH
|
$29M |
| 4 |
Insulet
PODD
|
$28.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$26.5M |
Top Sells
| 1 |
Insmed
INSM
|
$75M |
| 2 |
Intuitive Surgical
ISRG
|
$63.3M |
| 3 |
argenx
ARGX
|
$51.2M |
| 4 |
Boston Scientific
BSX
|
$44.6M |
| 5 |
Humana
HUM
|
$40M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Industrials | 0.05% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.02% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
AstraZeneca
AZN
$255B
| $3.29M | 0.05% |
42,200
+19,000
| +82% | +$1.48M |
|
|
WAY
102
Waystar Holding Corp
WAY
$6.53B
| $3.23M | 0.05% |
+150,000
| New | +$3.23M |
|
103
Cardinal Health
CAH
$36B
| $3.2M | 0.05% |
32,582
+29,582
| +986% | +$2.91M |
|
104
Recursion Pharmaceuticals
RXRX
$2.02B
| $3.19M | 0.05% |
425,810
+561
| +0.1% | +$4.21K |
|
|
ACCD
105
DELISTED
Accolade, Inc. Common Stock
ACCD
| $3.02M | 0.05% |
842,577
-3,961,937
| -82% | -$14.2M |
|
106
Outset Medical
OM
$245M
| $2.94M | 0.05% |
762,799
+190,440
| +33% | +$733K |
|
107
Gilead Sciences
GILD
$140B
| $2.67M | 0.04% |
38,934
+5,629
| +17% | +$386K |
|
108
Teladoc Health
TDOC
$1.37B
| $2.67M | 0.04% |
272,798
| – | – |
|
109
Teva Pharmaceuticals
TEVA
$21.5B
| $2.52M | 0.04% |
154,770
+12,557
| +9% | +$204K |
|
110
Pfizer
PFE
$141B
| $2.48M | 0.04% |
88,614
+54,780
| +162% | +$1.53M |
|
111
Doximity
DOCS
$12.6B
| $2.02M | 0.03% |
72,155
-71,910
| -50% | -$2.01M |
|
112
Dr. Reddy's Laboratories
RDY
$11.8B
| $1.78M | 0.03% |
23,328
-17,568
| -43% | -$1.34M |
|
|
MTEM
113
DELISTED
Molecular Templates, Inc.
MTEM
| $1.47M | 0.02% |
1,279,820
+250,000
| +24% | +$288K |
|
114
Biogen
BIIB
$20.8B
| $1.37M | 0.02% |
5,902
-106
| -2% | -$24.6K |
|
115
Certara
CERT
$1.69B
| $1.33M | 0.02% |
95,924
| – | – |
|
116
CVS Health
CVS
$93B
| $1.3M | 0.02% |
22,066
| – | – |
|
117
Encompass Health
EHC
$12.5B
| $1.19M | 0.02% |
13,868
-1,112
| -7% | -$95.4K |
|
118
Johnson & Johnson
JNJ
$429B
| $1.14M | 0.02% |
7,797
+1,377
| +21% | +$201K |
|
|
NVRO
119
DELISTED
NEVRO CORP.
NVRO
| $1.14M | 0.02% |
135,235
| – | – |
|
120
Alphabet (Google) Class C
GOOG
$2.79T
| $1.1M | 0.02% |
6,000
| – | – |
|
121
Vaxcyte
PCVX
$4.17B
| $1.07M | 0.02% |
14,210
+966
| +7% | +$72.9K |
|
122
Cytokinetics
CYTK
$5.98B
| $903K | 0.01% |
16,659
+1,019
| +7% | +$55.2K |
|
123
Krystal Biotech
KRYS
$4.35B
| $771K | 0.01% |
4,198
-612
| -13% | -$112K |
|
124
Tenet Healthcare
THC
$16.5B
| $720K | 0.01% |
5,414
+1,170
| +28% | +$156K |
|
125
Merus
MRUS
$5.04B
| $580K | 0.01% |
9,800
| – | – |
|